Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids

J Hepatol. 2017 Mar;66(3):657-659. doi: 10.1016/j.jhep.2016.11.015. Epub 2016 Nov 28.

Authors

Mirjana Ziemer¹, Eleni Koukoulioti², Susanne Beyer³, Jan C Simon³, Thomas Berg²

Affiliations

¹ Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, Germany. Electronic address: mirjana.ziemer@medizin.uni-leipzig.de.
² Universitätsklinikum Leipzig, Sektion Hepatologie, Klinik für Gastroenterologie und Rheumatologie, Germany.
³ Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie, Germany.

PMID: 27908801
DOI: 10.1016/j.jhep.2016.11.015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / adverse effects
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects
Autoimmune Diseases* / chemically induced
Autoimmune Diseases* / diagnosis
Autoimmune Diseases* / drug therapy
Autoimmune Diseases* / immunology
Budesonide / administration & dosage*
Chemical and Drug Induced Liver Injury* / diagnosis
Chemical and Drug Induced Liver Injury* / drug therapy
Chemical and Drug Induced Liver Injury* / immunology
Female
Glucocorticoids / administration & dosage
Humans
Liver Function Tests / methods
Melanoma / drug therapy*
Nivolumab* / administration & dosage
Nivolumab* / adverse effects
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Glucocorticoids
Nivolumab
Budesonide
pembrolizumab